On Invalid Date, Bioventus (NASDAQ: BVS) reported Q3 2022 earnings per share (EPS) of -$1.76, up 5,766.67% year over year. Total Bioventus earnings for the quarter were -$108.25 million. In the same quarter last year, Bioventus's earnings per share (EPS) was -$0.03.
On Invalid Date, Bioventus (NASDAQ: BVS) reported Q3 2022 revenue of $128.66 million up 18.16% year over year. In the same quarter last year, Bioventus's revenue was $108.89 million.
What was BVS's revenue growth in the past year?
As of Q1 2023, Bioventus's revenue has grown 29.47% year over year. This is 18.85 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 10.63%. Bioventus's revenue in the past year totalled $516.70 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.